Online inquiry

IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12686MR)

This product GTTS-WQ12686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12686MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7151MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ3440MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ6052MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ2885MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ3539MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ246MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ3168MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ13338MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW